Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that varies in its symptom presentation and functional impact across the lifespan. Although it is now recognized that ADHD may persist to adulthood, it often goes undetected in adults, being misdiagnosed as other psychiatric and frequently comorbid conditions. Diagnosis is complicated in that symptom presentation may vary as the individual transitions from childhood to adulthood. The use of diagnostic criteria and evidence-based tools can help to differentiate the diagnosis of ADHD in adults, particularly in the context of comorbidities. This is imperative because an accurate diagnosis not only facilitates early intervention but also offers a sense of relief as difficulties experienced at home and work are now explained.
This CME Outfitters activity will provide clinicians with the appropriate tools to facilitate the early detection of ADHD in adults, particularly within the context of comorbidities.
At the end of this CME/CE activity, participants should be able to:
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Psychiatrists, psychiatric nurses, pediatricians, primary care providers, PAs, nurse practitioners, nurses, and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Childress reports that she receives research support from Adlon Therapeutics L.P.; Akili Interactive Labs, Inc.; Allergan; Arbor Pharmaceuticals; KemPharm, Inc.; Neos Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Purdue Pharma L.P.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Tris Pharma, Inc. She reports that she is on the speakers bureau for Corium Inc.; Ironshore Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Tris Pharma, Inc. She reports that she is a consultant for Aardvark Therapeutics, Inc.; Corium Inc.; Jazz Pharmaceuticals, Inc.; KemPharm, Inc.; Lumos Pharma; Neos Therapeutics, Inc.; Noven Pharmaceuticals, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; and Tulex Pharmaceuticals. She reports that she receives writing support for Purdue Pharma L.P.; Supernus Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Cerulli has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.